Curtiss Puckett

Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the <scp>E</scp> fficacy and <scp>D</scp> urability of <scp>I</scp> nitial <scp>C</scp> ombination <scp>T</scp> herapy for <scp>T</scp> ype 2 <scp>D</scp> iabetes ( <scp>EDICT</scp> ): a randomized trial

M. A. Abdul‐Ghani, Curtiss Puckett, Curtis Triplitt et al. · Diabetes Obesity and Metabolism · 2014 · 196 citations · Full text

Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT

Muhammad Abdul‐Ghani, Curtiss Puckett, John M. Adams et al. · Diabetes Care · 2020 · 53 citations · Full text

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes ( <scp>EDICT</scp> )

Olga Lavynenko, Muhammad Abdul‐Ghani, Mariam Alatrach et al. · Diabetes Obesity and Metabolism · 2022 · 40 citations

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes

Deborah J. Wexler, Ian H. de Boer, Alokananda Ghosh et al. · JAMA Internal Medicine · 2023 · 31 citations · Full text

Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight

William I. Sivitz, Lawrence S. Phillips, Deborah J. Wexler et al. · Diabetes Care · 2020 · 24 citations · Full text